A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

Inclusion Criteria: * Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations * Have a diagnosis of haemophilia A * At enrolment on prophylactic treatment with Elocta, independent of participation in the study Exclusion Criteria: * Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study * Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit \[BU\]/mL) at the latest available inhibitor test